---
title: "Tonira Pharma Ltd(merged) (530155) — Share Price, Financials & Analysis"
symbol: "530155"
company: "Tonira Pharma Ltd(merged)"
canonical: "https://tapetide.com/stocks/530155"
isin: "INE844F01012"
bse_code: "530155"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:47:02.756Z"
---

# Tonira Pharma Ltd(merged) (530155)

Canonical page: https://tapetide.com/stocks/530155

## Company

- **BSE Code:** 530155
- **ISIN:** INE844F01012
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** DELISTED
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** tonira.com

## Latest Price

## Key Insights

### Strengths

- Debtor days have improved from 64.2 to 46.3 days.

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.12% over past five years.
- Company has a low return on equity of 1.45% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | -300% | -3% | — |
| revenue growth | -18% | 2% | 0% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 134 | 122 | 103 | 106 | 146 | 88 | 98 | 89 | 100 | 96 | 99 | 105 |
| Expenses | 111 | 97 | 77 | 82 | 125 | 62 | 73 | 62 | 68 | 67 | 77 | 83 |
| Operating Profit | 23 | 25 | 25 | 24 | 21 | 25 | 25 | 27 | 32 | 29 | 22 | 22 |
| OPM % | 17 | 21 | 25 | 23 | 14 | 29 | 25 | 30 | 32 | 30 | 22 | 21 |
| Other Income | 1 | 3 | 2 | 2 | 7 | 4 | 5 | 4 | -40 | 4 | 17 | 8 |
| Interest | 0 | 3 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Profit before tax | 20 | 21 | 21 | 21 | 21 | 22 | 22 | 24 | -16 | 25 | 32 | 22 |
| Tax % | 25 | 26 | 27 | 23 | 32 | 25 | 25 | 24 | -18 | 28 | 25 | 27 |
| Net Profit | 15 | 15 | 16 | 16 | 14 | 16 | 16 | 18 | -13 | 18 | 24 | 16 |
| EPS in Rs | 2.26 | 2.38 | 2.29 | 2.36 | 1.99 | 2.28 | 2.29 | 2.55 | -1.83 | 2.52 | 3.3 | 2.24 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 29.86 | 36.55 | 28.61 | 38.47 | 36.82 | 30.04 |
| Expenses | 23.59 | 29.67 | 29.55 | 30.18 | 29.97 | 26.31 |
| Operating Profit | 6.27 | 6.88 | -0.94 | 8.29 | 6.85 | 3.73 |
| OPM % | 21 | 18.82 | -3.29 | 21.55 | 18.6 | 12.42 |
| Other Income | 0.1 | 0.2 | -3.37 | -2.24 | 0.21 | 0.28 |
| Interest | 1.25 | 1.81 | 2.1 | 3.6 | 2.88 | 3.14 |
| Depreciation | 2.44 | 2.57 | 2.77 | 2.8 | 2.84 | 3.07 |
| Profit before tax | 2.68 | 2.7 | -9.18 | -0.35 | 1.34 | -2.2 |
| Tax % | 35.82 | 39.26 | -36.49 | 111.43 | 23.88 | -5.45 |
| Net Profit | 1.72 | 1.64 | -5.83 | -0.74 | 1.02 | -2.08 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 7.94 | 7.94 | 7.94 | 7.94 | 7.94 | 7.94 |
| Reserves | 10.49 | 12.13 | 6.3 | 5.25 | 6.39 | 4.31 |
| Borrowings | 21.41 | 19.68 | 28.91 | 28.38 | 31.3 | 36.74 |
| Other Liabilities | 6.1 | 10.13 | 8.97 | 11.47 | 8.06 | 6.62 |
| Total Liabilities | 45.94 | 49.88 | 52.12 | 53.04 | 53.69 | 55.61 |
| Fixed Assets | 27.3 | 27.79 | 26.21 | 24.13 | 24.55 | 23.41 |
| CWIP | 0 | 0 | 0.11 | 0.09 | 0.54 | 1.21 |
| Investments | 0.12 | 0.04 | 0.04 | 0.04 | 0.14 | 0.14 |
| Other Assets | 18.52 | 22.05 | 25.76 | 28.78 | 28.46 | 30.85 |
| Total Assets | 45.94 | 49.88 | 52.12 | 53.04 | 53.69 | 55.61 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -0.57 | 5.07 | -4.71 | 3.81 | 7.45 | -0.93 |
| Cash from Investing Activity | -5.62 | -3.27 | -1.17 | -0.72 | -3.82 | -2.63 |
| Cash from Financing Activity | 6.11 | -1.72 | 7.1 | -4.12 | -1.1 | 2.7 |
| Net Cash Flow | -0.08 | 0.08 | 1.22 | -1.03 | 2.53 | -0.86 |
| Free Cash Flow | -6.07 | 1.8 | -5.88 | 3.09 | 3.72 | -3.56 |
| CFO/OP | -8 | 74 | 501 | 47 | 115 | -20 |

### Ratios

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 68.09 | 40.24 | 69.15 | 83.49 | 62.75 | 46.29 |
| Inventory Days | 316.06 | 345.49 | 248.07 | 256.28 | 233.19 | 360.14 |
| Days Payable | 120 | 137.7 | 142.47 | 179.57 | 129.62 | 118.73 |
| Cash Conversion Cycle | 264.15 | 248.04 | 174.74 | 160.2 | 166.33 | 287.7 |
| Working Capital Days | 158.3 | 130.42 | 172.61 | 147.54 | 164.36 | 256.86 |
| ROCE % | — | 11.36 | -7.6 | 14.09 | 9.68 | 2.07 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 45.28% | 43.02% | 43.02% | 43.33% | 43.14% | 44.41% | 42.8% | 39.01% | 39.01% | 39.01% |
| FIIs | 0.25% | 0.36% | 0.34% | 0.34% | 0.21% | 0.21% | 3.37% | 5.2% | 5.07% | 3.45% |
| DIIs | 1.69% | 0.21% | 0.21% | 0.21% | 0.15% | 0.15% | 0% | 0.1% | 0% | 0.76% |
| Public | 52.78% | 56.41% | 56.43% | 56.12% | 56.5% | 55.24% | 53.83% | 55.69% | 55.91% | 56.78% |
| No. of Shareholders | 34770 | 43716 | 42972 | 39942 | 39084 | 39994 | 40530 | 50620 | 52976 | 52315 |

### Quarterly

| Category | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 42.8% | 42.8% | 40.97% | 40.97% | 39.01% | 39.01% | 39.01% | 39.01% | 39.01% | 39.01% | 39.01% | 39.01% |
| FIIs | 3.37% | 2.92% | 2.94% | 2.97% | 5.2% | 5.24% | 5.08% | 5.09% | 5.07% | 5.62% | 3.96% | 3.45% |
| DIIs | 0% | 0% | 0.02% | 0% | 0.1% | 0.01% | 0% | 0% | 0% | 0.33% | 0.52% | 0.76% |
| Public | 53.83% | 54.29% | 56.08% | 56.07% | 55.69% | 55.75% | 55.91% | 55.9% | 55.91% | 55.05% | 56.5% | 56.78% |
| No. of Shareholders | 40530 | 41173 | 43417 | 44160 | 50620 | 51810 | 54356 | 54443 | 52976 | 53546 | 53416 | 52315 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 2 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 801.12 | Buy |
| EMA (10) | 819.05 | Buy |
| SMA (20) | 764.14 | Buy |
| EMA (20) | 791.41 | Buy |
| SMA (50) | 811.66 | Buy |
| EMA (50) | 779.66 | Buy |
| SMA (100) | 762.46 | Buy |
| EMA (100) | 726.2 | Buy |
| SMA (200) | 562.73 | Buy |
| EMA (200) | 605.63 | Buy |

### Oscillators — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 81.21 | Sell |
| MACD (12,26,9) | 22.46 | Buy |
| Stochastic (14,3,3) | 94.97 | Sell |
| ADX (14) | 22.15 | Neutral |
| Williams %R (14) | -2.26 | Sell |
| ATR (14) | 46.9 | High Volatility |
| ROC (12) | 29.59 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 79.78 | Sell |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 23 Feb - Q3 revenue INR1,053m, PAT INR162m; INR160–170cr expansion; INR51.33cr Reliance order; dividend from FY26-27. --- checklist: - Review announcement content and context - Extract material financial … | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 23 Feb - Q3 revenue INR1,053m, PAT INR162m; INR160–170cr expansion; INR51.33cr Reliance order; dividend from FY26-27. --- checklist: - Review announcement content and context - Extract material financial …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8bbbdd25-1512-4e85-aaed-ccdd80b868db.pdf) |
| 19 Feb - Audio recording of Feb 19, 2026 investor/analyst conference call available on company website. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 19 Feb - Audio recording of Feb 19, 2026 investor/analyst conference call available on company website.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3869d2c3-b41d-4868-8e26-b7adfcf740b0.pdf) |
| 16 Feb - Newspaper Publication of Financial results for December 31, 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Feb - Newspaper Publication of Financial results for December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/10b9ddda-5b1c-47d4-a74b-b086b9304339.pdf) |
| 13 Feb - Standalone and consolidated unaudited results for quarter and nine months ended Dec 31, 2025; limited review by Mittal & Associates. | [Financial Results For December 31, 2025 13 Feb - Standalone and consolidated unaudited results for quarter and nine months ended Dec 31, 2025; limited review by Mittal & Associates.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/93524f9f-a0a3-4cb3-946d-8e2dd6a0a3fd.pdf) |
| 13 Feb - CFO Ramesh Pilani resigns due to age/health; effective May 12, 2026; accepted Feb 13, 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 13 Feb - CFO Ramesh Pilani resigns due to age/health; effective May 12, 2026; accepted Feb 13, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/97100c9e-dda8-4491-9721-321ff24ce571.pdf) |
| 13 Feb - Approved standalone and consolidated unaudited results for quarter and nine months ended Dec 31, 2025. | [Board Meeting Outcome for Results December 31, 2025 13 Feb - Approved standalone and consolidated unaudited results for quarter and nine months ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/720c63b9-933d-48cd-aa7a-87b8404902ae.pdf) |
| 11 Feb - Conference call on Feb 19, 2026 02:30 PM IST to discuss Q3 FY26 results and outlook. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Feb - Conference call on Feb 19, 2026 02:30 PM IST to discuss Q3 FY26 results and outlook.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7ceca97c-b478-4d0f-8b1a-0cde3a84f214.pdf) |
| — | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 23 Feb](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1D8E50EB_4484_4CE2_B117_08F4EED10F79_122909.pdf) |
| — | [Announcement under Regulation 30 (LODR)-Investor Presentation 19 Feb](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a863df0c-c593-4b4a-b695-ee000f2c7ae4.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ad58e3ca-49f0-4be5-b8c5-b6d772bdda13.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f1780496-d360-4c42-b47b-c82a2fdec020.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c95e031b-06b7-4d18-9b16-fdcbe8eb3240.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9443e53e-5967-44c8-b27b-05b45e6be5cc.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a35e4087-ba55-4685-9ab6-3953c76759ef.pdf) |
| Jun 2023 | [Concall - Jun 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0a503751-6ffe-42b3-815c-e5a9e4834773.pdf) |
| Jul 2022 | [Concall - Jul 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/15b5d055-70e6-41b0-bdca-88449bfa596d.pdf) |
| Jul 2022 | [Concall - Jul 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ca7c46a-01f2-4b85-9e71-82b76c5b6184.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a863df0c-c593-4b4a-b695-ee000f2c7ae4.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/84976cc5-4787-43f4-b988-e333600a9f76.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/75545c99-3959-4006-96c1-8d52fc491664.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b7afda78-c431-484e-b662-6c2d28cfbee7.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d156d0bb-0621-4fc0-ab0f-bd8a96d7c35a.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/500153/75747500153_16_09_22.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/500153/71067500153.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/500153/67878500153.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/500153/5001530319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/500153/5001530318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/500153/5001530317.pdf) |
| from bse | [Financial Year 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/500153/5001530316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:02.756Z.